RARA and acute promyelocytic leukemia: Mutations in PML and PML-RARA that arise in APL patients with arsenic-resistant disease are a unique research resource as these mutations are selected in vivo to be resistant to arsenic while still retaining the biological functions of PML that contribute to the disease phenotype.